OLMA — Olema Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1750284 ·
Last close
$7.22
Market Cap
$632.52M
52W High
$36.26
52W Low
$6.24
ADV30
1,426,785
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -77,525,000 | -73,599,000 | 441,070,000 | 47,522,000 | 72,233,000 |
| Jun 2026 | 0 | — | -67,179,000 | -63,200,000 | 486,578,000 | 48,599,000 | 56,014,000 |
| Mar 2026 | 0 | — | -57,986,000 | -53,089,000 | 530,645,000 | 52,547,000 | 50,167,000 |
| Dec 2025 | 0 | — | -50,084,000 | -46,061,000 | 533,430,000 | 48,301,000 | 54,871,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-177,322,000
Investing CF
$-71,213,000
Financing CF
$260,797,000
CapEx
$-900,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.35
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-787,445,000
Inventory
—
Receivables
$3,374,000
ST Investments
$366,249,000
EBIT TTM
$-252,774,000
Pretax Income TTM
$-235,949,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -178,698,000 | -162,451,000 | 533,430,000 | 54,871,000 | 478,559,000 | -146,716,000 |
| Dec 2024 | 0 | -142,258,000 | -129,474,000 | 450,979,000 | 42,015,000 | 408,964,000 | -104,351,000 |
| Dec 2023 | 0 | -104,961,000 | -96,655,000 | 276,945,000 | 23,050,000 | 253,895,000 | -83,727,000 |
| Dec 2022 | 0 | -106,988,000 | -104,787,000 | 215,645,000 | 18,099,000 | 197,546,000 | -82,065,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,941,000
NetIncome TTM
$-204,567,000
OpCashFlow TTM
—
Assets (Latest)
$486,578,000
Forward EPS
$-2.90
Max Pain — expiry 2026-12-18
max pain strike: $10.00 · spot: $7.06 · call oi: 4,410 · put oi: 1,368
Expected Move to 2026-12-18:
±$2.15
(30.45%) —
implied range
$4.91 –
$9.21
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | $630.12M | $9.84 | — |
| ALMS | ALUMIS INC. | $628.33M | $4.84 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
| GERN | GERON CORP | $644.24M | $1.00 | — |
News headlines (Yahoo Finance, 1h cache)
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
2026-11-18 07:30 · Yahoo
Olema Oncology to Participate in Upcoming Investor Conferences
2026-11-16 21:30 · Yahoo
Olema Oncology Announces Corporate Name Change
2026-11-12 14:00 · Yahoo
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
2026-11-10 12:00 · Yahoo
Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
2026-11-04 21:01 · Yahoo
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 21:30 · Yahoo
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
2026-09-14 12:10 · Yahoo
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
2026-08-10 20:01 · Yahoo
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?
2026-06-30 12:07 · Yahoo
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
2026-10-05 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.